Will Daman, Thiqa, and GIG Gulf cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Imkeldi is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by EDE?

The EDE named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; EDE review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any UAE-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. MOHAP, DHA, DOH, or Sharjah Health Authority verifies the active license; the EDE application records both the prescribing physician and the dispensing facility.

Can I receive Imkeldi at home?

The dispensing facility must be UAE-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative drug-only band: USD 3,500 to 5,000 per month. Delivered quote within 24h.Get my quote

Imkeldi access in the UAE: the EDE named-patient pathway

How patients in the United Arab Emirates legally obtain Imkeldi (imatinib oral solution) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in the UAE access Imkeldi (imatinib oral solution) for chronic myeloid leukemia (CML) and Philadelphia-chromosome-positive acute lymphoblastic leukemia in adult and pediatric patients through the EDE named-patient pathway, an Emirates Drug Establishment-administered mechanism that allows a UAE-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in AED.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Imkeldi reaches patients in the UAE

Imkeldi (imatinib oral solution, BCR-ABL tyrosine kinase inhibitor in a paediatric-friendly oral suspension formulation, FDA-approved May 2024 for chronic myeloid leukaemia in chronic phase, accelerated phase, or blast phase, and Philadelphia-chromosome-positive acute lymphoblastic leukaemia in adult and paediatric patients; the first FDA-approved oral solution of imatinib; marketed by Shorla Oncology) is not currently registered with MOHAP or EDE and is not visible on the MOHAP services portal at mohap.gov.ae/en/services as of 2026-05-31. UAE residents access Imkeldi through the EDE Permit to Import Medicines for Personal Use, the service transferred from MOHAP to EDE on 29 December 2025 per mohap.gov.ae/en/mte. The legal basis is Federal Law No. 8 of 2019. The Imkeldi-specific clinical justification must document: BCR-ABL1-positive CML or Ph+ ALL diagnosis (typically confirmed by quantitative RT-PCR or cytogenetics or FISH), patient age and weight-based dosing rationale (the suspension formulation is particularly relevant for paediatric or swallowing-impaired adult patients), prior imatinib-tablet experience or rationale for solution formulation (swallowing difficulty, paediatric dose-flexibility), and the prescribing oncology team's UAE-licensure status. EDE permits issue typically within several working days when documentation is complete.

Where Imkeldi is dispensed in the UAE

Imkeldi is dispensed in haematology, paediatric oncology, or general oncology outpatient settings with serial CBC, liver-function, and quantitative BCR-ABL transcript monitoring per the FDA label. UAE tertiary nodes include Al Jalila Children's Specialty Hospital Paediatric Oncology in Dubai at aljalilachildrens.ae (DHA paediatric-tertiary, the most-likely paediatric Imkeldi dispensing node); Cleveland Clinic Abu Dhabi (CCAD) Cancer Center and Paediatric Oncology in Abu Dhabi at clevelandclinicabudhabi.ae; Sheikh Shakhbout Medical City (SSMC) Department of Oncology in Abu Dhabi; Tawam Hospital (SEHA, affiliated with Johns Hopkins) Oncology and Paediatric Oncology in Al Ain at seha.ae; Burjeel Medical City Paediatric Oncology in Abu Dhabi; American Hospital Dubai Oncology; King's College Hospital London Dubai Oncology; and Mediclinic City Hospital Oncology in Dubai. Al Jalila Children's Specialty Hospital is the most-frequent paediatric-CML and Ph+-ALL referral nationally; CCAD and SSMC handle adult CML and Ph+ ALL.

What Imkeldi costs in the UAE

The US reference WAC for Imkeldi is approximately USD 2,800 to USD 3,200 per 90 mL bottle at the labelled paediatric weight-based dose; monthly cost varies with patient weight and dose, running USD 4,000 to USD 12,000 per Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. This is materially more expensive than generic imatinib tablets (now widely available globally including in the UAE at sub-USD-500-per-month price points for the 100 mg and 400 mg tablet formulations) because Imkeldi addresses the paediatric and swallowing-impaired-adult population for whom solution dose-flexibility is the value driver. No public AED benchmark for Imkeldi is observed on MOHAP or EDE drug-pricing services as of 2026-05-31; the drug is not currently UAE-registered. Do not estimate. Price snapshot: 2026-05-31. The AED is USD-pegged at 3.6725 AED per USD. Cost layers: ambient-temperature international logistics into the UAE (low to mid four-figure USD for the oral suspension), EDE personal-import permit fees (nominal), the dispensing paediatric oncology or haematology consultation and quantitative BCR-ABL monitoring fees, and Reserve Meds concierge fee itemised separately.

Funding and access barriers for Imkeldi in the UAE

Paediatric CML and Ph+ ALL are relatively rare; the UAE paediatric tertiary case load at Al Jalila, CCAD paediatric, and Tawam paediatric provides the clinical context. The historical standard for paediatric CML and Ph+ ALL has been crushed or compounded imatinib tablets (with quality-of-life and dosing-precision tradeoffs); Imkeldi's value is the FDA-approved oral solution formulation removing the compounding step. Public-sector funding: for Emirati national paediatric patients, Thiqa-administered Daman insurance at daman.ae covers specialty paediatric oncology at SEHA facilities; Dubai-resident Emirati nationals on Salama or ENAYA receive comparable cover. MOHAP-administered free care applies in the Northern Emirates. The cost differential between Imkeldi and generic compounded imatinib for the paediatric population means institutional formulary committees adjudicate Imkeldi versus continued generic imatinib compounding case-by-case. The Patient Affairs Department and Mohammed bin Rashid Foundation may grant funding for difficult cases. Major insurers (Daman, Bupa Arabia, AXA Gulf, MetLife, Sukoon, Cigna, Allianz, Mednet, Nextcare, NAS) require prior authorisation with documented inability to use crushed-tablet preparation or paediatric weight-band documentation. Out-of-pocket exposure is most material for expatriate paediatric oncology families. Shorla Oncology operates a patient-support programme at early-launch stage in 2026.

Recent regulatory and access news for Imkeldi

FDA approved Imkeldi (imatinib oral solution) on 10 May 2024 for CML in chronic, accelerated, or blast phase, and Ph+ ALL in adult and paediatric patients; the first FDA-approved oral solution of imatinib. The FDA approval letter is at accessdata.fda.gov/scripts/cder/daf. EMA pathway for the oral solution has not been formally announced at scale by Shorla Oncology as of 2026-05-31; check the EMA medicines database at ema.europa.eu/en/medicines for status. MOHAP transferred personal-use import permit service to EDE on 29 December 2025 per mohap.gov.ae/en/mte; UAE Imkeldi personal-import applications now route through ede.gov.ae. No MOHAP or EDE bulletin specific to Imkeldi has been observed.

Where Reserve Meds fits in Imkeldi cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace EDE, and we do not replace your dispensing pharmacy. For Imkeldi specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into the UAE, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Imkeldi case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the EDE application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Imkeldi's oral-solution presentation fills a real pediatric and dysphagia gap; the named-patient case typically rests on documented inability to swallow the standard tablet form of imatinib. UAE specialty referral typically routes these cases through Abu Dhabi or Dubai tertiary centres.

Next step

If your UAE physician has prescribed Imkeldi and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Imkeldi case Or message us on WhatsApp